Viromed Medical AG and NEBU-TEC Form Global Distribution Partnership for PulmoPlas in Veterinary Medicine

Viromed Medical AG ('Viromed'; ISIN: DE000A40ZVN7), a medical technology company specializing in cold plasma technology, has announced a global distribution partnership with NEBU-TEC International med. Produkte Eike Kern GmbH ('NEBU-TEC'). The agreement grants NEBU-TEC worldwide exclusive distribution rights for veterinary applications of PulmoPlas®, Viromed's cold plasma platform, when combined with NEBU-TEC's nebulization technology. This collaboration aims to open new therapeutic avenues for respiratory diseases, with an initial focus on pulmonary conditions in horses.

NEBU-TEC, a globally active medical technology company with 30 years of experience in aerosol medicine, develops and distributes inhalation devices for both human and veterinary medicine. The partnership leverages NEBU-TEC's engineering expertise and intellectual property portfolio to integrate Viromed's cold plasma technology into inhalation and nebulization solutions. The first product, PulmoPlas® vet, is scheduled for market launch later in 2026 and targets the European equine market, where respiratory diseases are prevalent among horses, especially in equestrian sports. No regulatory approval is required for this veterinary application, allowing for a streamlined introduction.

Uwe Perbandt, CEO of Viromed Medical AG, stated: 'The partnership with NEBU-TEC represents an important step in the international commercialization of our PulmoPlas® platform. Combining our cold plasma technology with NEBU-TEC's nebulization expertise opens up new fields of application in veterinary medicine and, going forward, also for applications in human medicine. We see attractive market potential here for this innovative approach.'

Eike Kern, Managing Director of NEBU-TEC, emphasized: 'The combination of inhalative application and cold plasma opens up new therapeutic possibilities. By bringing together complementary technologies, we are creating innovative and safe concepts for the treatment of both animals and humans – effective, safe and forward-looking.'

The devices used by NEBU-TEC are Class IIa medical devices under the EU Medical Device Regulation (MDR), which paves the way for future human medical applications of PulmoPlas® med. This partnership builds on Viromed's strategy to expand its strategic partnerships and position PulmoPlas® in additional international markets and applications. Viromed Medical AG, listed on the stock exchange since October 2022, operates through its wholly owned subsidiary Viromed Medical GmbH and has a broad customer base in the DACH region and beyond. More information about Viromed can be found at www.viromed-medical-ag.de. NEBU-TEC, headquartered in Elsenfeld, Germany, offers nebulization solutions for professional healthcare facilities and home use, as detailed on www.nebu-tec.de.

This announcement underscores the growing interest in cold plasma technology for therapeutic applications and highlights the potential for cross-sector innovations between veterinary and human medicine.